相关实验视频

Updated: Jul 5, 2025

A Knowledge Graph Approach to Elucidate the Role of Organellar Pathways in Disease via Biomedical Reports

A Knowledge Graph Approach to Elucidate the Role of Organellar Pathways in Disease via Biomedical Reports

Published on: October 13, 2023

以用户为中心的罕见疾病临床试验知识图 (RCTKG)

Jeremy Parker Yang¹, Devon Leadman², Richard M Ballew^2,3

¹University of Wisconsin-Madison, Madison, WI, US.

Studies in health technology and informatics

|January 25, 2024

概括

开发罕见疾病临床试验知识图 (RCTKG) 解决了罕见疾病药物开发方面的挑战. 这个知识图集了临床试验数据,以帮助罕见疾病研究和患者护理.

科学领域:

生物医学信息学生物医学信息学
临床试验管理临床试验管理
罕见疾病研究罕见疾病研究

背景情况:

由于患者人数较少和成本较高,为罕见疾病开发药物面临重大障碍.
分析现有的临床试验对于理解孤儿药物开发和为未来的研究提供信息至关重要.
数据的有限可访问性和标准化阻碍了罕见疾病临床试验的高效分析.

研究的目的:

开发一个以用户为中心的罕见疾病临床试验知识图 (RCTKG).
将公开可用的临床试验数据与来自遗传和罕见疾病 (GARD) 计划的罕见疾病信息相结合.
为公众提供语义和标准化资源,支持罕见疾病研究和临床实践.

主要方法:

为患者,医疗保健提供者和计算机专家定义了用户故事,以指导知识图的设计.
公开可用的临床试验数据将与罕见疾病信息相结合.
一个语义和标准化的数据模型将被用于RCTKG.

主要成果:

该项目旨在为罕见疾病临床试验创建一个全面的知识图.
该RCTKG将有助于更好地了解孤儿药物的临床开发状态.
以用户为中心的设计确保知识图满足不同利益相关者的需求.

结论:

开发的RCTKG将成为罕见病社区的宝贵资源.
它将支持NCATS/NIH的GARD计划以及更广泛的临床/研究社区.
该倡议旨在提高罕见病药物开发的效率和成功率.

关键词:

临床试验临床试验是指临床试验的临床试验.数据模型数据模型数据模型.知识图表知识图表罕见病是一种罕见的疾病.用户故事是用户故事.

更多相关视频

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila

Published on: August 20, 2019

相关概念视频

Hazard Ratio

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...

Kaplan-Meier Approach

Kaplan-Meier Approach

The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...